Stay Updated with the Latest BeOne Medicines AG 6160.HK News in Real Time
Find 6160.HK news now at Meyka AI. Stay informed with the latest BeOne Medicines AG stocks updates, including price news, market analysis, and expert insights.
AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal, Offering Nearly 50% Premium
AbbVie made a major move in the biotech sector on June 22, 2026, announcing a $10.9 billion deal to acquire Apogee Therapeutics. The transaction offers Apogee shareholders nearly a 50% premium and gives AbbVie access to a promising pipeline of immunology treatments. As competition grows in the market for inflammatory disease therapies, this acquisition could…
Traws Pharma Stock Drops 17% After UK Regulator Delays Flu Drug Trial
One regulatory hold is a setback. Two is a pattern, and Traws Pharma is now facing exactly that. On June 12, 2026, Traws Pharma (NASDAQ: TRAW) announced that its planned Phase 2a human influenza challenge study of tivoxavir marboxil (TXM) has been deferred following a negative review by the UK’s Medicines and Healthcare Products Regulatory…
Sun Pharmaceutical (SUNPHARMA) Shares Rise 0.32% as Pharma Giant Announces ₹5 Final Dividend Record Date
Sun Pharmaceutical Industries has once again grabbed investor attention in the Indian stock market. The Sun Pharmaceutical share price rose around 0.32% in recent trading sessions after the company announced a ₹5 final dividend for FY2025-26. The announcement also included key corporate updates, including the upcoming record date for dividend eligibility, which is now in…
Camurus Falls 7% as FDA Requests Reinspection for Oclaiz Approval
Shares of Camurus came under pressure after reports of a regulatory setback tied to its drug candidate Oclaiz. The stock dropped nearly 7% as investors reacted to news that the U.S. Food and Drug Administration (FDA) had requested a reinspection during the approval process. This development has created short-term uncertainty in the market. We from…
Concord Biotech Shares Jump 5.9% After US FDA Approves Tofacitinib Arthritis Drug
Shares of Concord Biotech saw strong buying interest after a key global development. The stock rose around 5.9% in recent trading sessions after news of a US FDA approval related to its Tofacitinib-based arthritis drug. The trigger is important. The US Food and Drug Administration (FDA) approval opens doors to the world’s largest pharmaceutical market….
Parabilis Medicines Targets Up to $2.3 Billion Valuation in Expanded U.S. IPO Amid Biotech Market Rally
Parabilis Medicines is aiming for a valuation of nearly $2.3 billion through an expanded U.S. initial public offering, highlighting renewed investor confidence in the biotechnology sector. The Cambridge, Massachusetts-based company increased the size of its offering as demand for biotech IPOs continues to improve following a challenging period for the industry. The company now plans…
GSK to Buy Nuvalent for $10.6 Billion, Paying $124 Per Share in All-Cash Deal
GSK has made a major move in the global pharmaceutical industry. The company has agreed to acquire Nuvalent for $10.6 billion in an all-cash deal. The offer price is $124 per share, which is about a 40% premium compared to the last closing price of Nuvalent. This is not a small deal. It is one…
Germany’s Healthcare Reform Faces Pushback: 16.3 Billion Euro Cuts Planned, June 03
Germany’s black-red coalition plans 16.3 billion euro healthcare cuts through higher drug copays, hospital spending caps, and reduced family coverage.
UK Seizes 12,000 Illegal Weight Loss Doses in Record Raid, May 31
UK authorities seize record 12,000 unlicensed weight loss drug doses in Northamptonshire. Two men arrested under Human Medicines Regulations 2012.